KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Gsk (GSK) Net Margin (2016 - 2026)

Gsk has reported Net Margin over the past 18 years, most recently at 22.77% for Q1 2026.

  • For Q1 2026, Net Margin rose 116.0% year-over-year to 22.77%; the TTM value through Mar 2026 reached 17.82%, up 507.0%, while the annual FY2025 figure was 17.5%, 929.0% up from the prior year.
  • Net Margin for Q1 2026 was 22.77% at Gsk, up from 7.38% in the prior quarter.
  • Over five years, Net Margin peaked at 138.22% in Q3 2022 and troughed at 0.72% in Q3 2024.
  • A 5-year average of 29.51% and a median of 21.44% in 2023 define the central range for Net Margin.
  • Biggest five-year swings in Net Margin: skyrocketed 12059bps in 2022 and later crashed -12025bps in 2023.
  • Year by year, Net Margin stood at 105.93% in 2022, then plummeted by -79bps to 22.04% in 2023, then tumbled by -34bps to 14.55% in 2024, then crashed by -49bps to 7.38% in 2025, then skyrocketed by 209bps to 22.77% in 2026.
  • Business Quant data shows Net Margin for GSK at 22.77% in Q1 2026, 7.38% in Q4 2025, and 23.55% in Q3 2025.